239 related articles for article (PubMed ID: 32472525)
21. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
Madan S; Dispenzieri A; Lacy MQ; Buadi F; Hayman SR; Zeldenrust SR; Rajkumar SV; Gertz MA; Kumar SK
Mayo Clin Proc; 2010 Mar; 85(3):232-8. PubMed ID: 20194151
[TBL] [Abstract][Full Text] [Related]
23. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.
Roccatello D; Fenoglio R; Naretto C; Baldovino S; Sciascia S; Ferro M; Rossi D
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050272
[TBL] [Abstract][Full Text] [Related]
24. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients.
Basset M; Milani P; Ferretti VV; Nuvolone M; Foli A; Benigna F; Nanci M; Bozzola M; Ripepi J; Sesta M; Russo F; Bosoni T; Klersy C; Albertini R; Merlini G; Palladini G
Clin Chem Lab Med; 2022 Feb; 60(3):386-393. PubMed ID: 35018751
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.
Hasib Sidiqi M; Gertz MA
Blood Cancer J; 2021 May; 11(5):90. PubMed ID: 33993188
[TBL] [Abstract][Full Text] [Related]
26. Primary systemic amyloidosis.
Comenzo RL
Curr Treat Options Oncol; 2000 Apr; 1(1):83-9. PubMed ID: 12057064
[TBL] [Abstract][Full Text] [Related]
27. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(5):44. PubMed ID: 29795248
[TBL] [Abstract][Full Text] [Related]
29. A patient with AL amyloidosis with negative free light chain results.
Milani P; Valentini V; Ferraro G; Basset M; Russo F; Foli A; Palladini G; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):1035-7. PubMed ID: 26677890
[TBL] [Abstract][Full Text] [Related]
30. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y
Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408
[TBL] [Abstract][Full Text] [Related]
31. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
[TBL] [Abstract][Full Text] [Related]
32. [AL amyloidosis, from diagnosis to treatment].
Villesuzanne C; Jaccard A; Nicol M
Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
[TBL] [Abstract][Full Text] [Related]
33. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
34. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
Nasr SH; Said SM; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Dispenzieri A; Buadi FK; Vrana JA; Theis JD; Dogan A; Leung N
Kidney Int; 2013 Mar; 83(3):463-70. PubMed ID: 23302715
[TBL] [Abstract][Full Text] [Related]
35. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
36. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
37. A unique case of light chain (AL) amyloidosis masquerading as hypophosphatemic osteomalacia.
Malhotra R; Guleria P; Barwad A; Pramanik R; Tandon N
Osteoporos Int; 2021 Feb; 32(2):387-392. PubMed ID: 32910218
[TBL] [Abstract][Full Text] [Related]
38. Bilateral kidney infarction due to primary Al amyloidosis: a first case report.
Mihout F; Joseph L; Brocheriou I; Leblond V; Varnous S; Ronco P; Plaisier E
Medicine (Baltimore); 2015 May; 94(17):e777. PubMed ID: 25929920
[TBL] [Abstract][Full Text] [Related]
39. Management of the elderly patient with AL amyloidosis.
Nuvolone M; Milani P; Palladini G; Merlini G
Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
[TBL] [Abstract][Full Text] [Related]
40. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.
Zanwar S; Gertz MA; Muchtar E
J Natl Compr Canc Netw; 2023 Jan; 21(1):83-90. PubMed ID: 36630897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
